|
1. |
Potential of β2-Adrenoceptor Agonists as Add-On Therapy for Multiple SclerosisFocus on Salbutamol (Albuterol) |
|
CNS Drugs,
Volume 16,
Issue 1,
2002,
Page 1-8
Karim Makhlouf,
Howard L. Weiner,
Samia J. Khoury,
Preview
|
PDF (277KB)
|
|
摘要:
The β2-adrenergic receptor agonist salbutamol (albuterol) has been used for many years in the treatment of bronchospasm in patients with asthma. In this patient group, salbutamol is a relatively safe and inexpensive drug, and is easy to administer.Within the last few years, there has been increasing evidence that salbutamol might have immunomodulatory properties bothin vitroandin vivo, in different animal models as well as in humans. This has led researchers to consider salbutamol as a potential therapy for several autoimmune diseases, including multiple sclerosis (MS).In this article, we review the literature presenting such evidence, and discuss the possible mechanisms by which salbutamol influences the immune system. We conclude that salbutamol might be an interesting add-on therapy in patients with MS and that further research is warranted.
ISSN:1172-7047
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Epidemiology and Treatment of Hypochondriasis |
|
CNS Drugs,
Volume 16,
Issue 1,
2002,
Page 9-22
Mónica Magariños,
Uzma Zafar,
Kore Nissenson,
Carlos Blanco,
Preview
|
PDF (276KB)
|
|
摘要:
Although hypochondriasis has been one of the most durable disease concepts in psychopathology, little is known about its epidemiology and treatment. In this article, we review the last three decades of research into these two aspects of hypochondriasis.According to DSM-IV, hypochondriasis is a distressing preoccupation with the fear or thought, based on physical sensations, that one has a serious disease. The prevalence of hypochondriasis in the general population is unknown; however, studies in primary care suggest that the prevalence in this setting is between 0.8 and 4.5%. There are, at present, no conclusive data about specific risk factors for hypochondriasis, although patients with hypochondriasis have higher rates of anxiety, depressive and other somatoform disorders than patients without the disorder. To date, there have been no studies documenting a genetic or familial predisposition for hypochondriasis, or for somatoform disorders in general.Cognitive behavioural therapy has been shown in controlled studies to be efficacious in the treatment of hypochondriasis. Although the evidence is stronger for individual therapy, group cognitive-behavioural therapy may also be useful. Other therapies such as supportive or psychoanalytical psychotherapy may be efficacious for certain patients, but the lack of standardised treatments and controlled studies makes them a less preferable treatment option at present.Little is known about the pharmacological treatment of primary hypochondriasis. The limited number of published studies and the absence of controlled trials make it impossible to be certain of the efficacy of existing medications. On the basis of the available information, however, it appears that the selective serotonin reuptake inhibitors hold promise for the treatment of this disorder. However, more information is needed for their efficacy to be clearly established.
ISSN:1172-7047
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Effects of Newer Antipsychotics on Extrapyramidal Function |
|
CNS Drugs,
Volume 16,
Issue 1,
2002,
Page 23-45
Daniel Tarsy,
Ross J. Baldessarini,
Frank I. Tarazi,
Preview
|
PDF (418KB)
|
|
摘要:
Following acceptance of clozapine as a superior antipsychotic agent with low risk of adverse extrapyramidal syndromes (EPS), such as dystonia, parkinsonism, akathisia or tardive dyskinesia, several novel antipsychotic drugs have been developed with properties modelled on those of clozapine. Though generally considered ‘atypical’ in their relatively low risk of inducing EPS, these agents vary considerably in their pharmacology and impact on neurological functioning.Although few comparative data are available, the atypical antipsychotics can be tentatively ranked by EPS risk (excluding akathisia and neuroleptic malignant syndrome) in the following order: clozapine < quetiapine < olanzapine = ziprasidone. At higher doses, risperidone is ranked with a higher EPS risk than olanzapine and ziprasidone, but its risk of EPS is lower with lower doses. In general, this ranking is inversely related to antidopaminergic (D2receptor) potency. The high antiserotonergic (5-HT2Areceptor) potency of risperidone, clozapine, ziprasidone and olanzapine, but not quetiapine, as well as the antimuscarinic activity of olanzapine and clozapine may also limit EPS.For the treatment of psychotic reactions to dopamine agonist therapy in Parkinson’s disease, clozapine is both effective and relatively well tolerated; quetiapine may be tolerated, olanzapine is not well tolerated, risperidone is poorly tolerated, and amisulpride and ziprasidone have not been well evaluated. Clozapine, perhaps because of its anticholinergic activity, can reduce parkinsonian tremor. It is useful for ongoing psychosis with tardive dyskinesia, especially for dystonic features. No atypical antipsychotic is clearly effective for motor abnormalities in Huntington’s disease or Tourette’s syndrome, and the effect of these drugs on other neurological disorders have been well evaluated in only small numbers of patients.In summary, with the exception of clozapine, and perhaps quetiapine, atypical antipsychotics have brought onlyrelativeavoidance of EPS, strongly encouraging continued searches for novel antipsychotic agents.
ISSN:1172-7047
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
The Bech-Rafaelsen Mania Scale in Clinical Trials of Therapies for Bipolar DisorderA 20-Year Review of its Use as an Outcome Measure |
|
CNS Drugs,
Volume 16,
Issue 1,
2002,
Page 47-63
Per Bech,
Preview
|
PDF (360KB)
|
|
摘要:
Over the last two decades the Bech-Rafaelsen Mania Scale (MAS) has been used extensively in trials that have assessed the efficacy of treatments for bipolar disorder. The extent of its use makes it possible to evaluate the psychometric properties of the scale according to the principles of internal validity, reliability, and external validity.Studies of the internal validity of the MAS have demonstrated that the simple sum of the 11 items of the scale is a sufficient statistic for the assessment of the severity of manic states. Both factor analysis and latent structure analysis (the Rasch analysis) have been used to demonstrate this. The total score of the MAS has been standardised such that scores below 15 indicate hypomania, scores around 20 indicate moderate mania, and scores around 28 indicate severe mania.The inter-observer reliability has been found to be high in a number of studies conducted in various countries.The MAS has shown an acceptable external validity, in terms of both sensitivity and responsiveness. Thus, the MAS was found to be superior to the Clinical Global Impression scale with regard to responsiveness, and sensitivity has been found to be adequate, with the MAS able to demonstrate large drug-placebo differences.Based on pretreatment scores, trials of antimanic therapies can be classified into: (i) ultrashort (1 week) therapy of severe mania; (ii) short-term therapy (3 to 8 weeks) of moderate mania; (iii) short-term therapy of hypomanic or mixed bipolar states; and (iv) long-term (12 months) therapy of bipolar states. The responsiveness of MAS is such that the scale has been able to demonstrated that typical antipsychotics are effective as an ultrashort therapy of severe mania; that lithium and anticonvulsants are effective in the short-term therapy of moderate mania; and that atypical antipsychotics, electroconvulsive therapy (ECT) and transcranial magnetic stimulation seem to have promising effects in the short-term therapy of moderate mania. In contrast, the scale has been used to demonstrate that calcium antagonists (e.g. verapamil) are ineffective in the treatment of mania. MAS has also been used to add to the literature on the evidence-based effect of lithium as a short-term therapy for hypomania or mixed bipolar states and as a long-term therapy of bipolar states.
ISSN:1172-7047
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Efficacy and Safety of Tianeptine in Major DepressionEvidence from a 3-Month Controlled Clinical Trial versus Paroxetine |
|
CNS Drugs,
Volume 16,
Issue 1,
2002,
Page 65-75
Lionel Waintraub,
Lucia Septien,
Paul Azoulay,
Preview
|
PDF (306KB)
|
|
摘要:
ObjectiveThis study was performed to compare the efficacy and safety of tianeptine and paroxetine in the treatment of major depression. Anxiolytic drug use was systematically reported to provide an indirect evaluation of the anxiolytic activity of both treatments. Zopiclone use was assessed to provide an indirect evaluation of the possible hypnotic activity of both treatments.Design and SettingThis was a 3-month controlled, randomised, double-blind clinical trial which involved 82 centres in France.Patients277 outpatients who met DSM-IV criteria for major depression.InterventionsPatients were treated with either tianeptine (12.5mg three times daily) or paroxetine (20mg once daily plus two placebo capsules). The drug dosages could be doubled after 3 weeks if required by the patient's medical state.Main Outcome Measures and ResultsThere was a significant decrease in the Montgomery-Åsberg Depression Rating Scale score in both groups (from 28.9 at baseline to 11 at endpoint in the tianeptine group, and from 29.6 to 11.6 in the paroxetine group) after 3 months of treatment. No significant difference was evident between the groups. Secondary criteria confirmed the antidepressant efficacy of both medications, with no difference between tianeptine and paroxetine (Hamilton Depression Rating Scale global score at endpoint, Clinical Global Impression final scores, number of responders, delay-to-response, rate of dosage doubling at day 21). The anxiolytic and hypnotic consumption rates decreased in both groups, with no significant difference between the groups. There was no significant difference in clinical safety parameters.ConclusionTianeptine appears to be as effective and as safe as paroxetine for the ambulatory treatment of major depression.
ISSN:1172-7047
出版商:ADIS
年代:2002
数据来源: ADIS
|
|